Lupin Limited has informed the Exchange regarding a press release dated May 26, 2025, titled "Lupin and SteinCares Enter into License and Supply Agreement for Ranibizumab inLatin America".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has signed a license and supply agreement with SteinCares to commercialize Ranibizumab in Latin America. Ranibizumab is a biologic used for treating eye conditions such as wet age-related macular degeneration (AMD). SteinCares is a Latin American specialty pharmaceutical company focused on biosimilars and complex therapies. Under the deal, SteinCares will handle registration, marketing, and distribution across the region, while Lupin will supply the product. The partnership gives Lupin access to Latin American markets without setting up its own infrastructure there.
This is a positive step for Lupin as it expands the global reach of its biosimilar portfolio with limited investment, though the financial impact is unlikely to be material in the near term. It signals the company's strategy to monetize biosimilars through regional partnerships.